Cardiovascular · Research Phase
C-type Natriuretic Peptide (CNP)
No lawful US pathway
01 · Overview
C-type natriuretic peptide (CNP) is a 22-amino acid member of the natriuretic peptide family that signals mainly through natriuretic peptide receptor B (NPR-B) and also through the NPR-C receptor (PMID 30903134). Unlike ANP and BNP it is produced largely by vascular endothelium and acts as a local regulator of vascular tone and angiogenesis rather than as a circulating renal hormone (PMID 30586761).
CNP also drives bone growth through effects on chondrocytes, which is the basis for its use in achondroplasia.
02 · Research summary & key findings
Vosoritide, an analogue of CNP, was FDA approved in November 2021 for achondroplasia; in a randomised, double-blind, placebo-controlled phase 3 trial (Lancet, 2020) it increased annualised growth velocity by 1.57 cm per year versus placebo over 52 weeks (PMID 32891212). Cardiovascular applications of CNP remain preclinical: in mice, loss of CNP from heart and vessel cells worsened heart failure and infarct size, and CNP administration rescued this effect through NPR-C (PMID 30903134), while endothelial CNP was shown to regulate angiogenesis and vascular remodeling (PMID 30586761).
03 · Regulatory status
C-type Natriuretic Peptide (CNP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
C-type Natriuretic Peptide (CNP) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 4 FDA-approved compounds in Cardiovascular
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Endogenous
References
- [1]Endothelial C-Type Natriuretic Peptide Is a Critical Regulator of Angiogenesis and Vascular Remodeling Circulation, 2019. PMID 30586761
- [2]C-type natriuretic peptide co-ordinates cardiac structure and function Eur Heart J, 2020. PMID 30903134
- [3]Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial Lancet, 2020. PMID 32891212
Primary literature
- PubMed: "C-type Natriuretic Peptide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "C-type Natriuretic Peptide"
Registered interventional and observational studies, including status and phase.
- PubChem: "C-type Natriuretic Peptide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cardiovascular
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.